Verdiva Bio Starts Phase 1 Trial of Weekly Oral VRB-103
LONDON and SAN FRANCISCO, July 30, 2026 Verdiva Bio announced that the first patient has been dosed in a...
Overweight
Advertisement
Boehringer Ingelheim Advances BI 3034701 into Phase II Obesity Trial
INGELHEIM, Germany, July 16, 2026 Boehringer Ingelheim has initiated a Phase II clinical trial evaluating BI 3034701, an investigational...
Zealand Pharma Reports Positive Phase 2 Petrelintide Data in Obesity
COPENHAGEN, Denmark, June 5, 2026 Zealand Pharma announced new results from its Phase 2 ZUPREME-1 clinical trial evaluating petrelintide,...
Structure Therapeutics Highlights Aleniglipron Phase 2b Success
SAN FRANCISCO, June 5, 2026 Structure Therapeutics Inc. announced the publication of detailed results from its Phase 2b ACCESS...
Zealand Pharma Highlights Positive Phase III Survodutide Results in Obesity
COPENHAGEN, Denmark, June 7, 2026 Zealand Pharma A/S announced that its partner Boehringer Ingelheim presented detailed results from the...
Advertisement
